MARAVAI LIFESCIENCES HOLDINGS INC (MRVI)

Sector: Health Care

    Home/Companies/MRVI/Annual Meeting

2026 Annual Meeting Analysis

MARAVAI LIFESCIENCES HOLDINGS INC · Meeting: May 26, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

1

Directors AGAINST

2

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Directors

1 FOR/2 AGAINST

Against Analysis

✗ AGAINST
Gregory T. LucierTSR underperformance 3yrpeer group trigger

Mr. Lucier has served since the November 2020 IPO, giving him full overlap with the 3-year underperformance period; MRVI's 3-year total return of -74.8% trails the company-disclosed peer group median of -29.3% by 45.5 percentage points, well above the 20-point trigger threshold that applies when absolute returns are negative; the 5-year check does not provide a mitigant because MRVI's 5-year return of -90.5% trails the peer 5-year median of -49.7% by 40.8 percentage points, also exceeding the 20-point threshold, confirming sustained rather than transient underperformance.

✗ AGAINST
Luke MarkerTSR underperformance 3yrpeer group trigger

Mr. Marker has served since the November 2020 IPO and has full overlap with the 3-year underperformance period; MRVI's 3-year total return of -74.8% lags the peer group median by 45.5 percentage points, exceeding the 20-point trigger; the 5-year check also fails (40.8pp gap versus a 20pp threshold), indicating sustained multi-year underperformance rather than a temporary trough, and his GTCR affiliation does not exempt him from accountability for stock performance outcomes during his tenure.

For Analysis

✓ FOR
Bernd Brust

Mr. Brust joined as CEO in June 2025 — less than 24 months ago — making him exempt from the TSR underperformance trigger under policy; his life sciences executive background is relevant and no other disqualifying factors apply.

Of the three nominees, only Bernd Brust receives a FOR vote due to his exemption as a director who joined within the past 24 months. Both Gregory Lucier and Luke Marker, who have served since the 2020 IPO, are voted AGAINST because MRVI's stock has fallen roughly 75% over three years while the company's own compensation peer group declined only about 29% — a gap of 45.5 percentage points that exceeds the policy's 20-point trigger — and the same pattern holds over five years, confirming the underperformance is not a recent anomaly.

Say on Pay

✓ FOR

CEO

Bernd Brust

Total Comp

$10,129,708

Prior Support

80.9%%

Mr. Brust joined as CEO in mid-2025 and his reported total compensation of approximately $10.1 million reflects a large new-hire equity package — including performance stock awards with meaningful stock-price hurdles ranging from $4 to $8 per share — rather than a recurring annual grant, and his base salary of $750,000 is reasonable for a CEO at a $1.3 billion company; the pay mix is heavily weighted toward variable, performance-linked equity (roughly 90% of total pay), satisfying the policy's requirement that the majority of pay be at risk. Prior-year say-on-pay support was 80.9%, above the 70% threshold that would require demonstrated changes, and the committee demonstrably responded to prior shareholder feedback by freezing base salaries, cutting 2025 annual equity grant values by 35–47% for continuing executives, extending vesting schedules, and refreshing the peer group; the company also has a formal clawback policy in place that complies with Dodd-Frank requirements.

Auditor Ratification

✓ FOR

Auditor

Deloitte & Touche LLP

Tenure

0 yrs

Audit Fees

$2,353,767

Non-Audit Fees

$0

Deloitte was newly appointed for fiscal year 2025 (replacing Ernst & Young, which audited prior years), making it a first-year engagement with no tenure concern; non-audit fees are zero, so the non-audit fee ratio is 0% — well below the 50% threshold — and Deloitte is a Big 4 firm appropriate for a $1.3 billion market-cap company.

Overall Assessment

The 2026 Maravai ballot presents three standard proposals: director elections, auditor ratification, and an advisory pay vote. We vote FOR the auditor (newly appointed Deloitte, no independence concerns) and FOR on Say on Pay (new CEO's pay is heavily performance-linked and the committee made tangible improvements after prior feedback), but vote AGAINST the two longest-tenured director nominees — Gregory Lucier and Luke Marker — because the stock has dramatically underperformed the company's own peer group over both three and five years, reflecting a sustained pattern rather than a temporary dip.

Filing date: April 24, 2026·Policy v1.2·high confidence

Compensation Peer Group

17 companies disclosed in 2026 proxy filing

TXG10x Genomics Inc.
AZTAAzenta, Inc.
TECHBio-Techne Corporation
CTKBCytek Biosciences, Inc.
FLGTFulgent Genetics, Inc.
GHGuardant Health
HALOHalozyme Therapeutics, Inc.
IRTCiRhythm Technologies, Inc.
LNTHLantheus Holdings, Inc.
NTRANatera, Inc.
NEOGNeogen Corporation
NEONeoGenomics, Inc.
RGENRepligen Corporation
SHCSotera Health Company
TNDMTandem Diabetes Care, Inc.
TWSTTwist Bioscience Corp.
VCYTVeracyte, Inc.